[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Rapport Therapeutics Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":129},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,82,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100643647","phase-3-study-evaluating-the-efficacy-and-safety-of-rap-219-in-adult-participants-with-focal-seizures-100643647",false,"NCT07594119","Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures","A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures","FOCUS 2","Inclusion Criteria:\n\n1. Age 18 - 75\n2. BMI 18-45 kg\u002Fm2\n3. Diagnosis of focal epilepsy for ≥24 months prior to Visit 1\n4. Report from at least 1 brain MRI or CT scan and 1 EEG study, each completed within 10 years prior to Visit 1, consistent with focal epilepsy diagnosis\n5. Concomitant use of between 1 and 3, inclusive, antiseizure medication(s) ASM(s) as maintenance, not including rescue or pro re nata (PRN) ASMs\n6. Ability to keep accurate daily focal seizure records using an e-diary\n\nExclusion Criteria:\n\n1. Known hypersensitivity or prior exposure to RAP-219.\n2. Unstable or uncontrolled serious medical, neurologic (other than focal epilepsy), or psychiatric condition that is ongoing or considered likely to recur\n3. Anticipated need for surgery during the study period\n4. Medical history of any of the following:\n\n   1. generalized epilepsy\n   2. focal preserved consciousness without observable manifestations (also known as focal aware nonmotor) as the participant's only seizure type\n   3. psychogenic nonepileptic seizure (PNES)\n   4. status epilepticus or seizure clusters (when individual seizures cannot be counted) within 12 months prior to Visit 1 (Day -56).\n   5. epilepsy surgery within 12 months prior to Visit 1 (Day -56).\n5. Participation in another clinical study of an investigational product within 12 weeks or 5 half-lives of this other investigational product","ALL","18 Years","75 Years",{"count":21,"type":22},312,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.",[28,29,30],"Focal Seizure","Epilepsy","Focal Epilepsy",[32,33],"Focal Preserved Consciousness","Focal Impaired Consciousness","RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":22},"2026-06",{"date":42,"type":22},"2029-09",{"name":44,"class":45},"Rapport Therapeutics Inc.","INDUSTRY",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100596517","phase-2-study-evaluating-the-efficacy-and-safety-of-rap-219-in-adult-participants-with-bipolar-i-disorder-100596517","NCT07046494","Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder","A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of RAP-219 for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder","Inclusion Criteria:\n\n* Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of bipolar I disorder, with or without psychotic symptoms, as confirmed by the Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT). Episode may contain mixed features, as confirmed by Montgomery-Åsberg Depression Rating Scale (MADRS).\n* Had at least one prior documented manic episode (with or without psychotic symptoms) that required treatment, within 5 years prior to Visit 1\n\nExclusion Criteria:\n\n* History of any of the following diagnoses: a. schizophrenia; schizoaffective disorder; major depressive disorder; moderate or severe substance or alcohol use disorder; as assessed by the SCID-5-CT b. delirium, dementia, amnestic, or other cognitive disorders; borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorders; by medical history and\u002For Investigator opinion Note: Any other current diagnoses must be discussed with the Medical Monitor.\n* Rapid cycler, defined as experiencing ≥4 distinct mood episodes (ie, manic or depressive) each meeting full DSM-5 criteria in the previous 12 months, and each separated by ≥2 months of full or partial remission, or a switch to an episode of the opposite polarity, as assessed by the SCID-5-CT","65 Years",{"count":56,"type":22},250,[58],"PHASE2","This is a clinical research study for an investigational drug called RAP-219 in participants with bipolar I disorder. This study is being conducted to determine if RAP-219 is safe and effective in participants experiencing mania associated with bipolar I disorder.",[61],"Bipolar 1 Disorder",[63,64,65,66,67,68,69,70,71,72],"Bipolar","Mania","Acute","In-patient","Manic State","Manic Episode","Mixed Features","Episode with Mixed Features","Mixed Mania","Bipolar Episode","2026-06-17",{"date":75,"type":38},"2026-06-22",{"date":77,"type":38},"2025-07-25",{"date":79,"type":22},"2026-11",{"name":44,"class":45},22,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":14,"acronym":87,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":26,"conditions":91,"keywords":92,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":99,"locationsCount":46},"100636299","phase-3-study-evaluating-the-efficacy-and-safety-of-rap-219-in-adult-participants-with-focal-seizures-focus-1-100636299","NCT07563881","Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1","FOCUS 1",{"count":89,"type":22},333,[25],[28,29,30],[32,33],"2026-06-12",{"date":95,"type":38},"2026-06-16",{"date":97,"type":38},"2026-06-05",{"date":42,"type":22},{"name":44,"class":45},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":23,"phases":110,"briefSummary":111,"conditions":112,"keywords":116,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},"100609809","phase-2-a-long-term-study-of-the-safety-and-effectiveness-of-rap-219-in-adults-with-focal-onset-seizures-100609809","NCT07219407","A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures","An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures","Inclusion Criteria:\n\n* Completion of the associated parent study (RAP-219-FOS-201) treatment period with acceptable tolerability, per Investigator.\n* Diagnosis of refractory focal epilepsy\n* Stable RNS(c) system settings\n* A demonstrated history of compliance with RNS(c) system data interrogation and upload\n* Good overall health other than focal epilepsy, per Investigator.\n* BMI ≥ 18 kg\u002Fm\\^2 and ≤ 45 kg\u002Fm\\^2\n* Willing and able to adhere to all aspects of the protocol.\n\nExclusion Criteria:\n\n* Known of hypersensitivity to RAP-219\n* Any clinically unstable or serious medical, neurological (other than epilepsy), psychological, or behavioral problem; laboratory or ECG finding that would increase participant risk or should otherwise exclude the patient from participation, as assessed by Investigator\n* Pregnancy, lactation, or individuals of reproductive potential who do not agree to simultaneously use two effective birth-control methods","70 Years",{"count":109,"type":22},30,[58],"This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.",[30,29,113,114,28,115],"Refractory Focal Epilepsy","Seizure","Focal Onset Seizure",[117,29,118,119],"Focal Seizures","RNS","Long episode","2026-01-22",{"date":122,"type":38},"2026-01-23",{"date":124,"type":38},"2025-12-15",{"date":126,"type":22},"2028-02-03",{"name":44,"class":45},7,""]